Developer docs
API playgroundTry for free, no card

Search company profiles

Vicebio

Full company profile

uuid0000dt7

Namestring
Vicebio
Legal namestring
Vicebio
Websiteurl
vicebio.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Vicebio was a UK-based biopharmaceutical company founded in 2019 that developed next-generation respiratory virus vaccines using the Molecular Clamp technology platform, licensed exclusively from the University of Queensland. The company's core technology stabilizes viral surface proteins in their prefusion state to elicit stronger immune responses, and Vicebio was the only company advancing this second-generation platform following earlier setbacks that caused false-positive HIV test results in prior applications. Its lead asset, VXB-241, is a bivalent vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), which had advanced into first-in-human clinical trials with interim data expected by mid-2025.

Vicebio operated as a pre-revenue, development-stage biotech with no commercial products and no disclosed pricing model. Revenue mechanics were tied to future vaccine commercialization (targeting healthcare providers and public health systems globally) rather than current sales; the company's economic value lay in clinical pipeline progression and the underlying Molecular Clamp platform IP. Go-to-market activity was conducted through scientific publications, clinical trial execution, and pharmaceutical industry partnerships rather than traditional sales channels. The company was venture-backed, with a $100M Series B closed in September 2024 led by TCGX alongside Goldman Sachs Alternatives, Avoro Ventures, venBio, UniQuest, and founding investor Medicxi.

In July 2025, Sanofi announced its acquisition of Vicebio for up to $1.6 billion ($1.15B upfront plus up to $450M in milestones), and completed the transaction on December 4, 2025, making Vicebio a wholly-owned subsidiary and representing the largest acquisition of a company commercializing IP from an Australian university. Leadership at the time of acquisition included Emmanuel Hanon (CEO), Giovanni Della Cioppa (CMO), Koen Huygens (CQO), and Jean Smal (CTO).

Short descriptiontext

Vicebio was a UK-based, pre-revenue biopharmaceutical company developing next-generation respiratory virus vaccines using the Molecular Clamp technology platform licensed from the University of Queensland. Its lead candidate, VXB-241, targets RSV and hMPV, and the company was acquired by Sanofi in December 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
respiratory virus vaccines, molecular clamp technology, vaccine development, biopharmaceutical research, multivalent vaccines
Industry2 codes
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Respiratory Vaccines
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1VXB-241
Description

Bivalent vaccine candidate targeting RSV and hMPV respiratory viruses, developed using Molecular Clamp technology, in first-in-human trials

techfundingnews.com
Core offering1 text field

Vicebio is a clinical-stage biopharmaceutical company developing next-generation respiratory virus vaccines using its proprietary Molecular Clamp technology platform, which stabilizes viral surface proteins in their prefusion state. The lead candidate, VXB-241, is a bivalent vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), and was advancing through first-in-human clinical trials prior to the company's acquisition.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Vicebio is an early-stage vaccine developer focused on respiratory viruses. The company utilizes a Molecular Clamp technology platform to develop multivalent vaccine candidates. Its lead product candidate is VXB-241, a bivalent vaccine targeting RSV and hMPV, which was in first-in-human trials. The company was acquired by Sanofi in December 2025.

Product and service2 records
1Molecular Clamp Technology Platform
CategoryVaccine Technology Platform
Description

Proprietary vaccine antigen-stabilization platform that locks viral surface glycoproteins in their prefusion state to enable design of recombinant subunit vaccines against respiratory viruses. Licensed from the University of Queensland and used as the foundational technology for Vicebio's pipeline.

2VXB-241
CategoryRespiratory Vaccines
Description

Bivalent vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), built on the Molecular Clamp platform. Advanced into first-in-human clinical trials as Vicebio's lead clinical asset.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-04
Description

Sanofi completed acquisition of Vicebio on December 4, 2025, adding a respiratory virus vaccine candidate and expanding Sanofi's capabilities in vaccine design, particularly involving its Molecular Clamp technology. Deal valued at $1.6 billion including $1.15 billion upfront and up to $450 million in milestone payments.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-07-22
Description

Vicebio licensed the Molecular Clamp vaccine technology from the University of Queensland. The deal represented the largest acquisition of a company commercializing intellectual property from an Australian university, validating 12 years of UQ research. UQ continues using the technology for pandemic preparedness research in collaboration with CEPI.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Arcturus Therapeutics develops self-amplifying mRNA vaccines targeting COVID-19, influenza, and RSV. With RSV-targeted candidates in development, Arcturus is an emerging peer competing in the same respiratory virus indication space as Vicebio using alternative nucleic acid-based technology.

TypeBroad incumbent
Description

Novavax is a vaccine developer using recombinant protein nanoparticle technology for influenza and COVID-19 vaccines, with adjuvanted approaches comparable to Vicebio's protein-subunit platform. As a broader vaccine incumbent with overlapping technology and respiratory indication focus, it represents an adjacent competitor in protein-based vaccine development.

TypeDirect peer
Description

Moderna is a leading mRNA vaccine developer with an approved RSV vaccine (mResvia) targeting the same respiratory virus space as Vicebio's VXB-241. Both companies compete in next-generation respiratory virus vaccine development, though Moderna uses mRNA while Vicebio uses a protein-subunit stabilization approach.

TypeOthers
Description

Sanofi acquired Vicebio in December 2025 for up to $1.6B and is now Vicebio's parent company. While not a peer in the traditional sense, Sanofi's broader vaccine franchise (including Fluzone, Beyfortus for RSV prevention in infants) provides the commercialization platform for Vicebio's Molecular Clamp candidates.

TypeBroad incumbent
Description

Pfizer markets Abrysvo, an approved RSV vaccine, and has extensive respiratory vaccine infrastructure. As a broad incumbent pharmaceutical company with overlapping vaccine capabilities, Pfizer competes with Vicebio's lead candidate in the same therapeutic area while having vastly greater commercial scale.

TypeEmerging player
Description

Blue Lake Biotechnology develops intranasal parainfluenza virus 5 (PIV5)-vectored vaccines for RSV and other respiratory pathogens. As a small emerging vaccine company focused on the same respiratory virus targets, it represents an emerging peer with overlapping scientific and indication focus.

TypeDirect peer
Description

Bavarian Nordic is developing MVA-BN RSV, a modified vaccinia Ankara-based RSV vaccine in late-stage clinical development. As a smaller specialty vaccine company focused on respiratory pathogens, it competes with Vicebio for clinical and commercial positioning in the RSV vaccine market.

TypeBroad incumbent
Description

GSK markets Arexvy, the first approved RSV vaccine for older adults, and has deep vaccine R&D and commercial capabilities. As a major vaccine incumbent with overlapping respiratory pathogen programs, GSK competes directly with Vicebio's bivalent RSV/hMPV candidate.

TypeDirect peer
Description

Icosavax developed VLP (virus-like particle) based vaccines targeting RSV and hMPV, the same two pathogens as Vicebio's VXB-241. The company was acquired by AstraZeneca in 2024, validating strategic interest in bivalent respiratory virus vaccines and making it a directly comparable technology and indication peer.

TypeEmerging player
Description

Meissa Vaccines is an early-stage company developing live-attenuated intranasal vaccines targeting RSV and other respiratory viruses. It shares Vicebio's focus on respiratory virus vaccine innovation but uses a different technological approach, making it an emerging peer in the same indication space.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vicebio

Respiratory Vaccinesvicebio.com

Vicebio was a UK-based, pre-revenue biopharmaceutical company developing next-generation respiratory virus vaccines using the Molecular Clamp technology platform licensed from the University of Queensland. Its lead candidate, VXB-241, targets RSV and hMPV, and the company was acquired by Sanofi in December 2025.

What Vicebio does

Vicebio was a UK-based biopharmaceutical company founded in 2019 that developed next-generation respiratory virus vaccines using the Molecular Clamp technology platform, licensed exclusively from the University of Queensland. The company's core technology stabilizes viral surface proteins in their prefusion state to elicit stronger immune responses, and Vicebio was the only company advancing this second-generation platform following earlier setbacks that caused false-positive HIV test results in prior applications. Its lead asset, VXB-241, is a bivalent vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), which had advanced into first-in-human clinical trials with interim data expected by mid-2025.

Vicebio operated as a pre-revenue, development-stage biotech with no commercial products and no disclosed pricing model. Revenue mechanics were tied to future vaccine commercialization (targeting healthcare providers and public health systems globally) rather than current sales; the company's economic value lay in clinical pipeline progression and the underlying Molecular Clamp platform IP. Go-to-market activity was conducted through scientific publications, clinical trial execution, and pharmaceutical industry partnerships rather than traditional sales channels. The company was venture-backed, with a $100M Series B closed in September 2024 led by TCGX alongside Goldman Sachs Alternatives, Avoro Ventures, venBio, UniQuest, and founding investor Medicxi.

In July 2025, Sanofi announced its acquisition of Vicebio for up to $1.6 billion ($1.15B upfront plus up to $450M in milestones), and completed the transaction on December 4, 2025, making Vicebio a wholly-owned subsidiary and representing the largest acquisition of a company commercializing IP from an Australian university. Leadership at the time of acquisition included Emmanuel Hanon (CEO), Giovanni Della Cioppa (CMO), Koen Huygens (CQO), and Jean Smal (CTO).

Vicebio firmographics

Firmographics
Name
Vicebio
Legal name
Vicebio
Website
https://vicebio.com
Company type
Private
Founded year
2019
Operating status
Acquired
Headcount range
11–50 employees
Short description
Vicebio was a UK-based, pre-revenue biopharmaceutical company developing next-generation respiratory virus vaccines using the Molecular Clamp technology platform licensed from the University of Queensland. Its lead candidate, VXB-241, targets RSV and hMPV, and the company was acquired by Sanofi in December 2025.
Ownership category
akta.pro rank

Vicebio industry classification

Industry
Product category
Respiratory Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Respiratory virus vaccines
  • Molecular clamp technology
  • Vaccine development
  • Biopharmaceutical research
  • Multivalent vaccines

Where Vicebio is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Markets served

Vicebio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Vicebio product offering

Product offering

Core offering

Vicebio is a clinical-stage biopharmaceutical company developing next-generation respiratory virus vaccines using its proprietary Molecular Clamp technology platform, which stabilizes viral surface proteins in their prefusion state. The lead candidate, VXB-241, is a bivalent vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), and was advancing through first-in-human clinical trials prior to the company's acquisition.

Product overview

Vicebio is an early-stage vaccine developer focused on respiratory viruses. The company utilizes a Molecular Clamp technology platform to develop multivalent vaccine candidates. Its lead product candidate is VXB-241, a bivalent vaccine targeting RSV and hMPV, which was in first-in-human trials. The company was acquired by Sanofi in December 2025.

Differentiator

Problem solved

Functional benefit

Brands

  • VXB-241: Bivalent vaccine candidate targeting RSV and hMPV respiratory viruses, developed using Molecular Clamp technology, in first-in-human trials

Products and services

  • Molecular Clamp Technology Platform Proprietary vaccine antigen-stabilization platform that locks viral surface glycoproteins in their prefusion state to enable design of recombinant subunit vaccines against respiratory viruses. Licensed from the University of Queensland and used as the foundational technology for Vicebio's pipeline.
  • VXB-241 Bivalent vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), built on the Molecular Clamp platform. Advanced into first-in-human clinical trials as Vicebio's lead clinical asset.

Companies that use Vicebio

Customer profile

Segments1 record

Ideal customer profiles1 record

Vicebio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Vicebio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • SanoficoreStrategic or Co-development Partner · 4 December 2025Sanofi completed acquisition of Vicebio on December 4, 2025, adding a respiratory virus vaccine candidate and expanding Sanofi's capabilities in vaccine design, particularly involving its Molecular Clamp technology. Deal valued at $1.6 billion including $1.15 billion upfront and up to $450 million in milestone payments.
  • University of QueenslandcoreTechnology or Integration · 22 July 2025Vicebio licensed the Molecular Clamp vaccine technology from the University of Queensland. The deal represented the largest acquisition of a company commercializing intellectual property from an Australian university, validating 12 years of UQ research. UQ continues using the technology for pandemic preparedness research in collaboration with CEPI.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Vicebio competitors and assessment

Company assessment

Emerging players

  • Arcturus Therapeutics: Arcturus Therapeutics develops self-amplifying mRNA vaccines targeting COVID-19, influenza, and RSV. With RSV-targeted candidates in development, Arcturus is an emerging peer competing in the same respiratory virus indication space as Vicebio using alternative nucleic acid-based technology.
  • Blue Lake Biotechnology: Blue Lake Biotechnology develops intranasal parainfluenza virus 5 (PIV5)-vectored vaccines for RSV and other respiratory pathogens. As a small emerging vaccine company focused on the same respiratory virus targets, it represents an emerging peer with overlapping scientific and indication focus.
  • Meissa Vaccines: Meissa Vaccines is an early-stage company developing live-attenuated intranasal vaccines targeting RSV and other respiratory viruses. It shares Vicebio's focus on respiratory virus vaccine innovation but uses a different technological approach, making it an emerging peer in the same indication space.

Broad incumbents

  • Novavax: Novavax is a vaccine developer using recombinant protein nanoparticle technology for influenza and COVID-19 vaccines, with adjuvanted approaches comparable to Vicebio's protein-subunit platform. As a broader vaccine incumbent with overlapping technology and respiratory indication focus, it represents an adjacent competitor in protein-based vaccine development.
  • Pfizer: Pfizer markets Abrysvo, an approved RSV vaccine, and has extensive respiratory vaccine infrastructure. As a broad incumbent pharmaceutical company with overlapping vaccine capabilities, Pfizer competes with Vicebio's lead candidate in the same therapeutic area while having vastly greater commercial scale.
  • GSK: GSK markets Arexvy, the first approved RSV vaccine for older adults, and has deep vaccine R&D and commercial capabilities. As a major vaccine incumbent with overlapping respiratory pathogen programs, GSK competes directly with Vicebio's bivalent RSV/hMPV candidate.

Direct peers

  • Moderna: Moderna is a leading mRNA vaccine developer with an approved RSV vaccine (mResvia) targeting the same respiratory virus space as Vicebio's VXB-241. Both companies compete in next-generation respiratory virus vaccine development, though Moderna uses mRNA while Vicebio uses a protein-subunit stabilization approach.
  • Bavarian Nordic: Bavarian Nordic is developing MVA-BN RSV, a modified vaccinia Ankara-based RSV vaccine in late-stage clinical development. As a smaller specialty vaccine company focused on respiratory pathogens, it competes with Vicebio for clinical and commercial positioning in the RSV vaccine market.
  • Icosavax: Icosavax developed VLP (virus-like particle) based vaccines targeting RSV and hMPV, the same two pathogens as Vicebio's VXB-241. The company was acquired by AstraZeneca in 2024, validating strategic interest in bivalent respiratory virus vaccines and making it a directly comparable technology and indication peer.

Others

  • Sanofi: Sanofi acquired Vicebio in December 2025 for up to $1.6B and is now Vicebio's parent company. While not a peer in the traditional sense, Sanofi's broader vaccine franchise (including Fluzone, Beyfortus for RSV prevention in infants) provides the commercialization platform for Vicebio's Molecular Clamp candidates.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Vicebio social profiles

Digital presence

Vicebio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vicebio leadership team

Management profile

Number of profiles

Profiles4 records

Vicebio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vicebio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vicebio

What does Vicebio do?

Vicebio is a clinical-stage biopharmaceutical company developing next-generation respiratory virus vaccines using its proprietary Molecular Clamp technology platform, which stabilizes viral surface proteins in their prefusion state. The lead candidate, VXB-241, is a bivalent vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), and was advancing through first-in-human clinical trials prior to the company's acquisition.

Is Vicebio a public or private company?

Vicebio is a private company. It is classified as corporate owned and is currently acquired.

When was Vicebio founded?

Vicebio was founded in 2019. It employs 11 to 50 people.

Where is Vicebio based?

Vicebio is headquartered in London, United Kingdom, in the Europe region.

Who are Vicebio's main competitors?

Emerging players on record are Arcturus Therapeutics, Blue Lake Biotechnology and Meissa Vaccines. Broad incumbents are Novavax, Pfizer and GSK. Direct peers are Moderna, Bavarian Nordic and Icosavax. Sanofi is listed as an others.

Does Vicebio have an API?

No public API is recorded for Vicebio.

What industry is Vicebio in?

Vicebio's product category is Respiratory Vaccines. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Australian Financial ReviewVirus ‘paperclip’ technology a boon for vaccine developmentPharmaceutical giant Sanofi acquired the University of Queensland spin-off Vicebio and its exclusive rights to molecular clamp technology for an upfront payment of $US1.15 billion plus potential ongoing payments of $US450 million. The transaction is described as the most lucrative Australian university research commercialisation agreement ever negotiated, with significant implications for future vaccine development.European Biotechnology8 European VC firms to watch in 2026Eight European VC firms are profiled for 2026, including Jeito Capital, Sofinnova Partners, and Medicxi, with fund sizes and recent exits. The list highlights firms that closed new biotech funds in the past year, such as Jeito II at $1.2 billion and Medicxi V at €500 million. The firms are positioned as shaping the continent's investment landscape amid tighter capital.pharmaphorumClosed & Collaborative H2 2025: Mergers, acquisitions, partnerships, collaborations, and strategic agreementsThe pharma and healthcare sector saw significant dealmaking activity in H2 2025, marked by acquisitions, partnerships, and platform licensing across manufacturing, clinical research, oncology, and data-driven technologies. Notable transactions included Sanofi's $1.6 billion acquisition of Vicebio for respiratory vaccine technology and Terumo's purchase of OrganOx in one of the UK's largest medtech exits. The period reflected a strategic shift toward precision medicine collaborations, with companies leveraging partnerships in RNA, ADC, radiopharmaceutical, and AI-enabled platforms to compress development timelines, share risk, and unlock data-driven insights.European Medical JournalUK pharma M&A stalled, biotech thrived in 2025Pharmaceutical and life sciences accounted for 21% of UK healthcare M&A in 2025, down from 27% a year earlier, with inbound activity falling by more than a quarter as UK assets faced caution from overseas buyers. Despite overall UK dealmaking declining 10–15%, healthcare transactions held steady at 280 deals, outperforming other sectors, with biopharma and biotechnology deals representing 35% of activity. Notable transactions included AstraZeneca's £774.2m acquisition of cell therapy company EsoBiotec and Sanofi's £1.2bn takeover of respiratory vaccine biotech Vicebio.EIN PresswireAntimicrobials Market Valuation, ROI Potential & Long-Term Growth Prospects 2026–2036Future Market Insights released a market report projecting the global antimicrobials market to grow from USD 117.6 billion in 2026 to USD 197.0 billion by 2036, representing a compound annual growth rate of 5.3%, driven by an industry shift toward narrower-spectrum agents, combination therapies, and advanced delivery systems amid rising antimicrobial resistance concerns. The report identifies antibacterial agents as the leading segment with 45.3% market share, oral formulations holding 57.8% dominance by route of administration, and North America led by the United States as the fastest-growing region at 5.9% CAGR. Key recent developments include GSK partnering with the Fleming Initiative for AI-driven solutions (November 2025), Sanofi acquiring Vicebio for respiratory virus vaccines (December 2025), and Roche expanding the pediatric label for Xofluza (January 2026).FierceBiotech'Things are looking up': British biotechs consider going public after yearslong IPO droughtThe U.K. biotech sector is showing early signs of renewed IPO interest in 2026 after years of drought, with industry sources noting that British companies are eyeing the Nasdaq for listings given the depth of capital markets and quality investors there. M&A activity was a bright spot in 2025, with Merck paying $10 billion for Verona Pharma and Sanofi acquiring ViceBio for $1.2 billion, though equity financing for U.K. biotechs fell 49% year-on-year to £1.9 billion. Government initiatives to attract pension fund investment into homegrown biotechs and strong fourth-quarter funding momentum are fueling optimism for a substantially better funding environment in 2026.In VivoJ.P. Morgan Notebook: Big Pharmas Weigh In On Vaccines, AI And MFNAt the J.P. Morgan Healthcare Conference Day 3, major pharmaceutical companies outlined strategic priorities including Sanofi's vaccine M&A push with recent acquisitions of Dynavax for $2.2bn and Vicebio for $1.15bn, Bristol Myers Squibb's most-favored-nation drug pricing agreement with the Trump administration providing Eliquis free to Medicaid patients, and Boehringer Ingelheim preparing for six Phase III readouts of obesity/MASH drug survodutide in 2026. AstraZeneca announced the acquisition of AI firm Modella AI to enhance pathology foundation models, Gilead's CMO discussed external innovation priorities in immunology and oncology including in-vivo CAR-T expansion, and GSK highlighted AI-driven R&D improvements including Phase II COPD combination trials. Samsung Epis Holdings disclosed plans to secure 20 biosimilars by 2030 and advance its first novel ADC candidate SBE303 into clinical studies.DealformaInfectious R&D Partnerships, M&A and Venture FundingQ3 2025 marked a resurgence in infectious disease investments, with R&D partnerships totaling 11 deals worth $966 million, M&A activity surging to 7 transactions valued at $19.5 billion, and venture funding reaching $369 million across 12 rounds. Key M&A transactions included BD's $17.5 billion Reverse Morris Trust merger with Waters Corporation to form a combined diagnostics company, Sanofi's $1.2 billion acquisition of Vicebio for RSV and hMPV vaccines, and CorMedix's $300 million purchase of Melinta Therapeutics for approved antifungals and antibiotics.Yahoo​Sanofi (SNY) Completes the Acquisition of VicebioSanofi announced on December 4 the completion of its acquisition of Vicebio, a clinical-stage biotechnology company focused on developing multi-pathogen vaccines for respiratory viral infections. The strategic acquisition brings Vicebio's early-stage vaccine candidate for respiratory syncytial virus and human metapneumovirus into Sanofi's portfolio, along with access to Vicebio's Molecular Clamp technology for enhanced vaccine design. Additionally, Sanofi's jointly developed drug Dupilumab with Regeneron received European Commission approval on November 25 for treating moderate-to-severe chronic spontaneous urticaria in patients 12 years and older.VenturesIncreased investment needed in early-stage homegrown techSanofi acquired Australian biotech company Vicebio Limited in what is described as the largest acquisition of a company commercialising intellectual property from an Australian university, representing a landmark deal for the local innovation sector. The transaction resulted from more than a decade of research commercialisation work by UniQuest using The University of Queensland's Molecular Clamp technology, which was also previously used in COVID-19 vaccine development. The opinion piece argues that Australia must increase its appetite for risk capital and early-stage investment to retain more value from homegrown research and boost jobs for Australians.